Menu

Markets

Research

News

Learn
Paper trading
AI Chat
Get the app WatchlistsPortfoliosAlerts
Sign in

BridgeBio Pharma, Inc. BBIO

Set alert

Price alert · BBIO

All alert types
76.10 USD +1.10 +1.47%

As of Nov 3, 10:53 AM ET

Bid
76.06 × 1
Ask
76.13 × 1
75.25 Day range 76.79
61.37 52-week range 90.17
YTD
-0.51%
1 year
+22.78%
Open
75.50
Prev close
75.00
Mkt cap
14.87B
Vol
701.51K
Avg vol
2.60M
EPS
-3.03
P/E
0.00
Div yield
0.00%
More statistics
Low
75.25
High
76.79
Forward P/E
-231.49
Beta
0.94
Short ratio
6.50
Inst. own
99.87%
Dividend
0.00
Ex-div date
Earnings
Feb 23, 2027
50-d avg
70.27
200-d avg
72.74
1y target
107.11

30m chart

Chart tools
Interval
1m5m15m30m

Built from the cached five-day intraday bars.

Events in this range
  • Oct 29, 2026Earnings: -0.42; estimate -0.54225; surprise 22.54%
  • Oct 30, 2026Rating: Morgan Stanley · Overweight → Overweight
  • Oct 30, 2026Rating: TD Cowen · Buy → Buy
  • Nov 2, 2026Rating: Canaccord Genuity · Buy → Buy
Signals (7)
NameTimeAgo
SMA: BullishNov 3, 9:55 AM58 minutes ago
SMA: BearishNov 2, 1:25 PM21 hours ago
MACD: Sell SignalNov 2, 12:25 PM22 hours ago
RSI: OverboughtNov 2, 9:55 AM1 day ago
SMA: BullishOct 30, 9:55 AM4 days ago
RSI: OverboughtOct 30, 9:55 AM4 days ago
SMA: BearishOct 29, 12:55 PM4 days ago

Analyst view

Consensus: strong buy

Strong buy
Price target (mean) 107.11 +40.7% upside
Target (low)
80.00
Target (mean)
107.11
Target (high)
156.00
Ratings (0m) 21 18 buy · 3 hold · 0 sell
  • Strong buy4
  • Buy14
  • Hold3
  • Sell0
  • Strong sell0

Recommendation trend

  • This month 21
  • 1 month ago 22
  • 2 months ago 22

Earnings and revenue estimates

Consensus for the coming quarters and fiscal years

BBIO analyst estimates
PeriodEPS estimateLow – highYear agoEPS growthRevenue estimateRevenue growthAnalysts
Current quarter-0.379-0.63 – 0.13-0.93893+59.6%302.35M+96.1%5
Next quarter-0.30-0.52 – -0.18-0.84+64.3%336.46M+73.0%3
Current year-2.25-2.41 – -2.09-3.78+40.5%1.09B+117.9%2
Next year-0.18795-2.42 – 1.31-2.25+91.7%1.66B+52.0%6

Upgrades and downgrades

The latest rating changes

BBIO analyst upgrades and downgrades
DateFirmActionFromTo
Nov 2, 2026Canaccord GenuityMaintainedBuyBuy
Oct 30, 2026TD CowenMaintainedBuyBuy
Oct 30, 2026Morgan StanleyMaintainedOverweightOverweight
Oct 21, 2026Morgan StanleyMaintainedOverweightOverweight
Oct 19, 2026CitigroupMaintainedNeutralNeutral
Oct 19, 2026Piper SandlerMaintainedOverweightOverweight
Oct 7, 2026BarclaysMaintainedOverweightOverweight
Sep 10, 2026HC Wainwright & Co.ReiteratedBuyBuy
Sep 2, 2026HC Wainwright & Co.ReiteratedBuyBuy
Sep 1, 2026MizuhoMaintainedOutperformOutperform
Aug 12, 2026Truist SecuritiesMaintainedBuyBuy
Aug 12, 2026Canaccord GenuityMaintainedBuyBuy
Aug 12, 2026JP MorganMaintainedOverweightOverweight
Aug 11, 2026B of A SecuritiesMaintainedBuyBuy
Aug 11, 2026TD CowenMaintainedBuyBuy
Aug 11, 2026Morgan StanleyMaintainedOverweightOverweight
Aug 11, 2026Piper SandlerMaintainedOverweightOverweight
Aug 11, 2026Wells FargoMaintainedOverweightOverweight
Jul 16, 2026CitigroupMaintainedNeutralNeutral
Jul 13, 2026HC Wainwright & Co.MaintainedBuyBuy
Jun 16, 2026MizuhoMaintainedOutperformOutperform
Jun 3, 2026Canaccord GenuityInitiated—Buy
May 28, 2026Morgan StanleyMaintainedOverweightOverweight
May 28, 2026HC Wainwright & Co.ReiteratedBuyBuy
May 26, 2026Raymond JamesDowngradeOutperformMarket Perform
May 19, 2026CitigroupInitiated—Neutral
May 11, 2026HC Wainwright & Co.MaintainedBuyBuy
May 8, 2026Evercore ISI GroupMaintainedOutperformOutperform
Apr 29, 2026Truist SecuritiesMaintainedBuyBuy
Apr 29, 2026HC Wainwright & Co.ReiteratedBuyBuy